Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 ...
Medscape3d
Hyponatremia in the Patient With Subarachnoid Hemorrhage
Hyponatremia commonly occurs in patients with aneurysmal subarachnoid hemorrhage. Two mechanisms have been proposed as causes: syndrome of inappropriate anti-diuretic hormone and cerebral salt ...
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors$15 ...
Grace Therapeutics reports positive Phase 3 trial results for GTx-104
Grace Therapeutics Inc. (NASDAQ:GRCE), a $32.85 million market cap biotechnology company whose stock has gained over 37% in the past six months, has announced successful outcomes from its Phase 3 ...
Grace Therapeutics secures up to $30 million financing
PRINCETON, N.J. - Grace Therapeutics, Inc. (NASDAQ:GRCE), a biopharmaceutical company focused on developing treatments for ...
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...
Woman with subarachnoid haemorrhage treated with minimally invasive procedure at private hospital in Chennai
A team of doctors including neurologists, interventional radiologists, and neurosurgeons decided to use a minimally invasive approach called endovascular intervention. In this, a specialised device is ...